HEALTH TECHNOLOGY

FDA-approved Investigator-initiated Pre-market Clinical Trial of LAmbre™ Plus LAA Closure System Obtained Medical Insurance Coverage in the US

LifeTech Scientific Corporation | September 06, 2022 | Read time : 02:00 min

FDA-approved

LifeTech Scientific Corporation is pleased to announce that on 30 August 2022, an FDA-approved investigator-initiated pre-market clinical trial of its proprietary LAmbre™ Plus Left Atrial Appendage (LAA) Closure System has obtained medical insurance coverage in the United States, meaning that all patient enrollment of the clinical trial will be fully covered by the USA medical insurance. This is expected to facilitate the marketing and registration process of the innovative device in the United States and provide strong clinical data to support the development of the device in the global market.

The investigator-initiated pre-market clinical trial received FDA approval in March 2022. This prospective, randomized, controlled, multicenter clinical trial aims to evaluate the safety and efficacy of the implantation of LAmbre™ Plus LAA occluder in non-valvular atrial fibrillation patients with large and/or irregularly shaped appendages, as compared to oral anticoagulants. The trial is planning to enroll more than 3,000 subjects from up to 75 investigational sites in the United States and undertake more than 1,500 implantations of the LAmbre™ Plus LAA occluders at a fee. After reaching the established clinical objectives and conditions, the company will submit the marketing application of the device to the FDA.

"This is a great milestone in LifeTech's international roadmap. Our LAA occluders had been successfully implanted in the United States on a basis of 'compassionate use', providing a new treatment for non-valvular atrial fibrillation patients with irregularly shaped appendages. Today, the approval for the first ever USA based investigator-initiated pre-market clinical trial and the medical insurance coverage gives us a greater confidence to further accelerate our process for providing this innovative, safe and effective stroke prevention solution to patients in the United States,"

Mr. Xie Yuehui, Chairman and CEO, LifeTech Scientific Corporation

About the LAmbre™ Plus LAA Closure System
LAmbre™ Plus LAA Closure System is independently developed by LifeTech Scientific Corporation. The device closes patient's left atrial appendage through percutaneous occlusion procedure to prevent stroke caused by detachment of thrombus from the left atrial appendage. LAmbre™ Plus LAA Closure System is a structural optimized version of the LAmbre™ LAA Closure System, which is an advanced medical device in the industry in terms of design and technology, and currently it has been widely used in over 40 countries with nearly 20,000 cases in clinical application around the world.

About LifeTech Scientific Corporation
Established in 1999, LifeTech Scientific Corporation (1302.HK) is committed to the R&D, manufacture, and sales of minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases. The company has a comprehensive product portfolio in the treatment of structural heart diseases, peripheral vascular diseases, bradycardia, neurological, neoplastic and respiratory diseases, alongside a unique iron-based bioresorbable technology. To date, 14 of the company's products have been approved as innovative medical devices by the National Medical Products Administration, and with a global reach of over 100 countries and regions, the company is currently one of the few domestic companies in China with a highly internationalized business structure.

Spotlight

Painful and disabled knee joint resulting from osteoarthritis, rheumatoid arthritis, traumatic arthritis where one or more compartments are involved. Correction of varus, valgus, or posttraumatic deformity. Correction or revision of unsuccessful osteotomy, arthrodesis, or failure of previous joint replacement procedure.

Spotlight

Painful and disabled knee joint resulting from osteoarthritis, rheumatoid arthritis, traumatic arthritis where one or more compartments are involved. Correction of varus, valgus, or posttraumatic deformity. Correction or revision of unsuccessful osteotomy, arthrodesis, or failure of previous joint replacement procedure.

Related News

FUTURE OF HEALTHCARE

DispatchHealth Raises More Than $330 Million to Expand Its Technology-Enabled Ecosystem of High Acuity Care in the Home

DispatchHealth | November 24, 2022

DispatchHealth, the nation's first comprehensive in-home, high acuity medical care provider announced it has raised more than $330 million in combined equity and debt financing. The equity round of $259 million was led by Optum Ventures, with participation from new investors Adams Street Partners, Blue Shield of California, among others, and continued support from existing investors Humana, Echo Health Ventures, Questa Capital and Oak HC/FT. K2 HealthVentures, Silicon Valley Bank and SVB Capital provided debt financing of $75 million, with up to an additional $75 million available for growth initiatives, bringing the total raised to more than $400 million. In the United States, $4 trillion is spent on healthcare annually and it is projected to exceed $6 trillion by 2028. With more than a third of this spend on care delivered in traditional brick-and-mortar facilities, the healthcare industry has reached a watershed moment. DispatchHealth's in-home, high acuity care model aligns health plans, health systems, at-risk provider groups and patients with complex care needs by delivering a value-based alternative to high-cost settings such as the emergency room, hospital ward or skilled nursing facility, reducing medical costs while improving clinical outcomes and patient and provider satisfaction. "For the past seven years, we have been building a comprehensive ecosystem of high acuity care in the home. Our proven approach to delivering healthcare to complex patients in their homes will continue to transform healthcare. This round of funding is a testament to what we and our passionate team members have created at DispatchHealth and the belief our partners have in our leading-edge care model." Dr. Mark Prather, Co-Founder and CEO of DispatchHealth Today, DispatchHealth provides high acuity care to complex patients across 34 states and has developed innovative relationships with health plans, provider groups, health systems, employers, senior living facilities, and home health organizations to deliver a better, more coordinated healthcare experience. DispatchHealth is also one of the largest and most experienced providers of Advanced Care, a hospital alternative, and Extended Care, a skilled nursing facility alternative. To coordinate the complex ecosystem of in-home care, DispatchHealth has created an operating system for high acuity care in the home. The proprietary technology platform uses real-time data insights to manage all aspects of the in-home care experience, including logistics, onboarding, risk stratification, care coordination and analytics that elevate the clinical practice and drive improved outcomes. DispatchHealth will use the financing to Expand its proven in-home high acuity care ecosystem in existing markets and key expansion markets; Accelerate its technology platform development to deliver consistent and scalable patient-centric care; and, Strategically grow its portfolio of in-home system of care and last mile care capabilities. "DispatchHealth is transforming the healthcare industry by improving access to outcomes-driven, high-quality, in-home care and delivering on the enhanced experience patients deserve. Optum Ventures is honored to deepen our relationship with DispatchHealth and its experienced leadership team as they continue to expand their reach of high acuity, in-home care to serve patients with complex care needs across the nation," said Laura Veroneau, Managing Partner at Optum Ventures. "DispatchHealth's comprehensive and unique ecosystem of in-home care is compelling. Adams Street is thrilled to support DispatchHealth as they expand their system of care, particularly their high acuity hospitalization substitution model. We believe DispatchHealth is positioned to catalyze important and necessary advances in the healthcare industry," said Tom Bremner, a Partner at Adams Street Partners. About DispatchHealth  DispatchHealth brings the power of the hospital to the comfort of the home. DispatchHealth is building the leading in-home system of care and offers on-demand acute care and an advanced level of medical care for people of all ages in the comfort of their own homes. DispatchHealth's emergency medicine and internal medicine trained medical teams are equipped with all the tools necessary to treat common to complex injuries and illnesses. DispatchHealth works closely with payers, providers, health systems, EMS, employer groups and others to deliver care in the home to reduce unnecessary emergency room visits, hospital stays and readmissions. Acute Care medical teams are available seven days a week, evenings and holidays and can be requested online or via a quick phone call. DispatchHealth is partnered with most major insurance companies. About Optum Ventures Optum Ventures is the independent venture fund of UnitedHealth Group. Optum Ventures invests in digital health companies that use data and insights to help improve consumers' access to healthcare services and how care is delivered and paid for, and that make the health care system more reliable and easier to navigate. About Adams Street Partners Adams Street Partners is a global private markets investment manager with investments in more than thirty countries across five continents. The firm is 100% employee-owned and has $50 billion in assets under management. Adams Street strives to generate actionable investment insights across market cycles by drawing on 50 years of private markets experience, proprietary intelligence, and trusted relationships. Adams Street has offices in Austin, Beijing, Boston, Chicago, London, Menlo Park, Munich, New York, Seoul, Singapore, and Tokyo.

Read More

HEALTH TECHNOLOGY

Gradient AI Acquires Healthcare Analytics Business Unit from Prognos Health to Expand Medical Underwriting Offering

Gradient AI and Prognos Health | October 11, 2022

Self Insurance Institute of America conference -October 10, 2022- Gradient AI, a leading enterprise software provider of artificial intelligence (AI) solutions in the insurance industry announced that it has acquired Prognos Health’s analytics business underwriting unit to leverage data from the company’s large collection of integrated medical records and lab data via its real-world data marketplace. The acquisition will enable Gradient AI to expand its medical database capabilities by integrating Prognos Health’s data with SAIL™, Gradient AI’s leading medical underwriting solution. Medical records on 325 million de-identified U.S. patients can be accessed through the Prognos Marketplace. In addition to retrieving medical and prescription claims data customers will now have access to lab data, which has been a missing factor for many insurers when predicting group risk. According to the Centers for Disease Control and Prevention (CDC), 70% of today’s medical decisions depend on laboratory test results because they are among the best indicators of disease severity and progression. With the acquisition, Gradient AI will become the only company in the group medical insurance market to provide medical, prescription, and lab data from a single source. Insurers will benefit by having further insight into group members' health for more informed risk assessment and improved underwriting accuracy. “The acquisition of Prognos underwriting business unit is a game changer. Our combined solution will provide a holistic picture of group health risk that has never before been possible. Insurers will now have a single point of access to multiple data sources, covering medical, prescription and lab data improving their abilities to project group health assessments and costs with much greater confidence.” Stan Smith, CEO and founder, Gradient AI Gradient AI aspires to continue its innovation in assessing group health risks. In the future, the company plans to expand its data sources to include information from Electronic Health Records and claims-based patient population data. “We are excited to join forces with Gradient AI to create a next-generation industry leading solution for group health insurance,” said Sundeep Bhan, co-founder and CEO, Prognos Health. “Gradient AI is a clear leader in healthcare analytics underwriting. Prognos looks forward to supporting the rapid innovation at Gradient AI by leveraging the most relevant data from the Prognos Marketplace. With the sale of the underwriting business unit, Prognos will continue to focus on our real-word data marketplace and democratizing data to improve health.” About Prognos Health Prognos Health’s mission is to democratize data to improve health. Prognos is focused on enabling data accessibility for everyone by leveraging technology and our clinical experience. We are removing data silos and fragmentation by linking, normalizing and standardizing data. We allow data to flow more freely and help organizations make the best data-informed decisions by simplifying and streamlining access to fit-for-purpose, multi-dimensional real-world data sets. Prognos is the leading real-world data marketplace with integrated RWD on 325M patients. All data purchased is available on the Datavant token, making it interoperable with other patient-level data that has been tokenized using Datavant. About Gradient AI Gradient AI is a leading provider of proven artificial intelligence (AI) solutions for the insurance industry. Its solutions improve loss ratios and profitability by predicting underwriting and claim risks with greater accuracy, as well as reducing quote turnaround times and claim expenses through intelligent automation. Unlike other solutions that use a limited claims and underwriting dataset, Gradient's software-as-a-service (SaaS) platform leverages a vast dataset comprised of tens of millions of policies and claims. It also incorporates numerous other features including economic, health, geographic and demographic information. Customers include some of the most recognized insurance carriers, MGAs, TPAs, risk pools, PEOs and large self-insureds across all major lines of insurance. By using Gradient AI’s solutions, insurers of all types achieve a better return on risk.

Read More

HEALTH TECHNOLOGY

Netsmart Announces Intent to Become a Qualified Health Information Network to Drive the Evolution of Interoperability

Netsmart | September 23, 2022

Netsmart, the developer of the industry-leading CareFabric® platform for human services, post-acute care providers and payers announced its intent to apply to join the Trusted Exchange Framework and Common Agreement to become a Qualified Health Information Network. By supporting TEFCA, Netsmart continues its decade-long advancement of interoperability strategies to facilitate an open exchange of longitudinal healthcare data that will benefit individuals receiving care across the healthcare ecosystem. Once accepted as a QHIN, Netsmart will be part of a first-of-a-kind national data sharing network that will determine new standards for both private and public sectors. The Office of the National Coordinator for Health Information Technology is leading the charge and will oversee the QHIN process through the designation of The Sequoia Project as the recognized coordinating entity. Netsmart has been collaborating with the ONC and The Sequoia Project to help develop and provide feedback on the principles and procedures put forth by TEFCA. Netsmart is a longtime leader and advocate for open networks and interoperability standards to prioritize the needs of providers, clinicians, patients, and their families. This open network approach is in contrast to technology vendors who in some cases have sought to carve out proprietary networks that stifle the future of care coordination. The open and secure sharing of data is required to achieve effective care coordination that Netsmart supports as a founding member of the Carequality interoperability framework. The Netsmart network, CareConnect™, was built to offer clients seamless integration of health data and one point of access to the larger health data ecosystem. With the CareConnect solution, Netsmart was one of the first healthcare IT vendors to utilize the new 360X closed-loop referral standards in a production environment to bring to life true interoperability to minimize manual data entry which streamlines transitions of care and care coordination and reduces medication errors. By empowering providers to digitize their enterprise, Netsmart clients are projected to perform more than 3 billion secure health data exchanges facilitated through CareConnect in 2022. “It has always been our objective as a healthcare technology partner to offer comprehensive solutions and services that allow providers to remain competitive in a landscape that requires coordinated care and value-based practices for success. Becoming a Qualified Health Information Network aligns with our established history of being at the forefront of driving interoperability. As we take the next step in the evolution of data exchange, we look forward to collaborating with other healthcare IT vendors applying to participate as a QHIN to expand access to open networks for consumers nationwide.” Netsmart CEO Mike Valentine About Netsmart Netsmart, a leading provider of Software as a Service technology and services solutions, designs, builds and delivers electronic health records, health information exchanges, analytics and telehealth solutions and services that are powerful, intuitive and easy-to-use. Our platform provides accurate, up-to-date information that is easily accessible to care team members in the human services and post-acute care (which is comprised of home care and hospice and senior living) and payer markets. We make the complex simple and personalized so our clients can concentrate on what they do best: provide services and treatment that support whole-person care. By leveraging the powerful Netsmart network, care providers can seamlessly and securely integrate information across communities, collaborate on the most effective treatments and improve outcomes for those in their care. Our streamlined systems and personalized workflows put relevant information at the fingertips of users when and where they need it.

Read More